ChenSZhuBLuoZWangYHuQZhouL. The fibrosis-5 index predicts major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Angiology. 2025;76:734-742.
Méndez-SánchezNBugianesiEGishRG, et al.Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-90.
4.
MuzurovićEMikhailidisDPMantzorosC. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119:154770.
5.
MuzurovićEPengCCBelangerMJSanoudouDMikhailidisDPMantzorosCS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79:1319-26.
6.
SalmenTSerbanoiuLIBicaIC, et al.A critical view over the newest antidiabetic molecules in light of efficacy-A systematic review and meta-analysis. Int J Mol Sci. 2023;24:9760.
7.
BicaICStoicaRASalmenT, et al.The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials. Medicina. 2023;59:1136.
8.
GiglioRVMuzurovićEMPattiAM, et al.Treatment with proprotein convertase subtilisin/Kexin type 9 inhibitors (PCSK9i): current evidence for expanding the paradigm?J Cardiovasc Pharmacol Therapeut. 2023;28:10742484231186855.
9.
MaedaDKanzakiYSakaneK, et al.Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with acute heart failure. ESC Heart Fail. 2022;9:1380-7.
10.
KumariBKumarRSharmaS, et al.Diagnostic accuracy of FIB-4 and FIB-5 scores as compared to fibroscan for assessment of liver fibrosis in patients with non-alcoholic fatty liver disease. Cureus. 2021;13:e17622.
11.
PrennerSBKumarAZhaoL, et al.Effect of serum albumin levels in patients with heart failure with preserved ejection fraction (from the TOPCAT trial). Am J Cardiol. 2020;125:575-82.
12.
van DeursenVMEdwardsCCotterG, et al.Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. J Card Fail. 2014;20:407-13.
13.
WangZLiGHuangR, et al.Prognostic value of fibrosis-5 index combined with C-reactive protein in patients with acute decompensated heart failure. BMC Cardiovasc Disord. 2023;23:492.
14.
MuzurovićEvan der LelyAJGurnellM. AST to ALT ratio and peripheral arterial disease in a hypertensive population-is there a link?Angiology. 2021;72:905-7.
15.
LuukkonenPKQadriSAhlholmN, et al.Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022;76:526-35.
16.
KokkorakisMBoutariCKatsikiNMantzorosCS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023;147:155664.
17.
MuzurovićEMikhailidisDPMantzorosC. Commentary: from mice to men: in search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism. 2020;109:154305.
18.
SanyalAJShankarSSCalleRA, et al.Non-invasive biomarkers of nonalcoholic steatohepatitis: the FNIH NIMBLE project. Nat Med. 2022;28:430-2.
19.
MalladiNAlamMJMaulikSKBanerjeeSK. The role of platelets in non-alcoholic fatty liver disease: from pathophysiology to therapeutics. Prostag Other Lipid Mediat. 2023;169:106766.
20.
LiuHHCaoYXJinJL, et al.Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention. J Am Heart Assoc. 2021;10:e018869.
